

GLAXOSMITHKLINE PLC
Form 6-K
September 10, 2010

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934

For period ending September 2010

GlaxoSmithKline plc
(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address of principal executive offices)

Indicate by check mark whether the registrant files or
will file annual reports under cover Form 20-F or Form 40-F

Form 20-F Form 40-F

--

Indicate by check mark whether the registrant by furnishing the
information contained in this Form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934.

Yes No

--

Issued: Friday, 10th September 2010, London, U.K.

GSK publishes historical quarterly turnover by product.

For the reporting period ended 30th June 2010, GlaxoSmithKline (GSK) adopted a revised presentation for the analysis of its pharmaceutical turnover by product and therapeutic area that identified the revenues from the Emerging Markets segment separately from the Rest of World. In order to assist comparability with historically published data, this release includes the pharmaceutical turnover by product for each quarter since the period ended 31st March 2008 presented on a like-for-like basis with the information for the period ended 30th June 2010.

This information differs from the previously published information for presentational reasons only, including principally:

- The separation of the Emerging Markets segment product revenues from Rest of World;
- The creation of the new Dermatological therapeutic area and the reclassification of certain products into this category from previously reported categories;
 - The creation of ViiV Healthcare in 2009.

S M Bicknell
Company Secretary

10 September 2010

GlaxoSmithKline (GSK) together with its subsidiary undertakings, the 'Group' - one of the world's leading research-based pharmaceutical and healthcare companies - is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For further information please visit www.gsk.com

| | | | |
|-----------------------------|-----------------|--------------------|-----------------|
| Enquiries: | UK Media | David Mawdsley | (020) 8047 5564 |
| | | Claire Brough | (020) 8047 5502 |
| | | Alexandra Harrison | (020) 8047 5502 |
| | | Stephen Rea | (020) 8047 5502 |
| | | Jo Revill | (020) 8047 5502 |
| | US Media | Nancy Pekarek | (919) 483 2839 |
| | | Mary Anne Rhyne | (919) 483 2839 |
| | | Kevin Colgan | (919) 483 2839 |
| | | Sarah Alspach | (919) 483 2839 |
| European Analyst / Investor | Sally Ferguson | (020) 8047 5543 | |
| | Gary Davies | (020) 8047 5503 | |
| US Analyst / Investor | Tom Curry | (215) 751 5419 | |
| | Jen Hill Baxter | (215) 751 7002 | |

CER growth

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

In order to illustrate underlying performance, it is the Group's practice to discuss its results in terms of constant exchange rate (CER) growth. This represents growth calculated as if the exchange rates used to determine the results of overseas companies in Sterling had remained unchanged from those used in the comparative period.

Brand names and partner acknowledgements

Brand names appearing in italics throughout this document are trademarks of GSK or associated companies or used under licence by the Group.

This Announcement does not constitute statutory accounts of the Group within the meaning of sections 434(3) and 435(3) of the Companies Act 2006. The information for 2008 and 2009 has been derived from the full Group accounts published in the Annual Report 2008 and 2009, which has been delivered to the Registrar of Companies and on which the report of the independent auditors was unqualified and did not contain a statement under section 498 of the Companies Act 2006.

Cautionary statement regarding forward-looking statements

Under the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Factors that may affect GSK's operations are described under 'Risk Factors' in the 'Business Review' in the company's Annual Report on Form 20-F for 2009.

GlaxoSmithKline plc, 980 Great West Road, Brentford, Middlesex TW8 9GS, United Kingdom

Registered in England and Wales. Registered number: 3888792

Pharmaceuticals turnover

Three months ended 31st March 2010

| | Total | | USA | | Europe | | Emerging Markets | | Rest of World | |
|-------------------|-------|------|-----|------|--------|------|------------------|------|---------------|------|
| | £m | CER% | £m | CER% | £m | CER% | £m | CER% | £m | CER% |
| Respiratory | 1,766 | 6 | 805 | 3 | 569 | 6 | 143 | 30 | 249 | 4 |
| Avamys/Veramyst | 46 | 52 | 17 | (10) | 13 | 56 | 5 | >100 | 11 | >100 |
| Flixonase/Flonase | 45 | (30) | 6 | (40) | 10 | (17) | 9 | 13 | 20 | (41) |
| Flixotide/Flovent | 196 | 5 | 99 | 8 | 45 | (6) | 14 | 75 | 38 | (5) |
| Seretide/Advair | 1,264 | 9 | 630 | 4 | 423 | 10 | 80 | 28 | 131 | 23 |
| Serevent | 51 | (16) | 16 | (11) | 26 | (16) | - | - | 9 | (18) |
| Ventolin | 116 | 3 | 35 | - | 37 | - | 24 | 14 | 20 | - |
| Zyrtec | 20 | 17 | - | - | - | - | 2 | 100 | 18 | 12 |
| Anti-virals | 358 | (44) | 154 | (42) | 35 | (78) | 47 | 9 | 122 | (27) |

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

| | | | | | | | | | | |
|-------------------------------|-------|------|-----|------|-----|------|-----|-------|-----|------|
| Hepsera | 29 | 11 | - | - | - | - | 12 | - | 17 | 21 |
| Relenza | 84 | (60) | 30 | >100 | 2 | (97) | 1 | - | 51 | (49) |
| Valtrex | 176 | (46) | 107 | (55) | 23 | (43) | 5 | - | 41 | - |
| Zeffix | 52 | 4 | 3 | - | 7 | - | 29 | 11 | 13 | (7) |
| Central nervous system | 417 | (13) | 136 | (32) | 140 | (2) | 45 | 14 | 96 | 3 |
| Imigran/Imitrex | 57 | (9) | 24 | (11) | 22 | (12) | 1 | - | 10 | - |
| Lamictal | 120 | (11) | 61 | (23) | 37 | (3) | 12 | 8 | 10 | 67 |
| Requip | 55 | 14 | 10 | 38 | 36 | 13 | - | - | 9 | - |
| Seroxat/Paxil | 106 | (12) | 10 | (29) | 22 | (21) | 15 | - | 59 | (7) |
| Treximet | 13 | 7 | 13 | 7 | - | - | - | - | - | - |
| Wellbutrin | 20 | (67) | 8 | (85) | 9 | 50 | 3 | 50 | - | (50) |
| Cardiovascular and urogenital | 570 | 9 | 337 | 6 | 153 | 11 | 28 | 25 | 52 | 21 |
| Arixtra | 70 | 25 | 39 | 27 | 26 | 23 | 2 | 100 | 3 | - |
| Avodart | 139 | 20 | 76 | 12 | 40 | 17 | 7 | 60 | 16 | 88 |
| Coreg | 42 | (12) | 42 | (12) | - | - | - | - | - | - |
| Fraxiparine | 56 | 4 | - | - | 43 | - | 11 | 22 | 2 | - |
| Lovaza | 107 | 9 | 107 | 10 | - | - | - | - | - | - |
| Vesicare | 25 | 13 | 25 | 13 | - | - | - | - | - | - |
| Volibris | 9 | >100 | - | - | 8 | >100 | - | - | 1 | - |
| Metabolic | 230 | (18) | 89 | (36) | 61 | (7) | 31 | 18 | 49 | 2 |
| Avandia products | 169 | (10) | 89 | (14) | 38 | (12) | 19 | 6 | 23 | 4 |
| Bonviva/Boniva | 23 | (63) | - | - | 20 | (5) | - | - | 3 | - |
| Anti-bacterials | 356 | (6) | 24 | (10) | 142 | (21) | 146 | 11 | 44 | 5 |
| Augmentin | 160 | (10) | 8 | (44) | 63 | (23) | 70 | 12 | 19 | - |
| Oncology and emesis | 169 | 23 | 92 | 41 | 50 | - | 12 | 8 | 15 | 27 |
| Arzerra | 5 | - | 5 | - | - | - | - | - | - | - |
| Hycamtin | 40 | - | 24 | - | 13 | (7) | 2 | 100 | 1 | - |
| Promacta | 6 | >100 | 6 | >100 | - | - | - | - | - | - |
| Tyverb/Tykerb | 53 | 62 | 17 | 73 | 24 | 41 | 5 | 67 | 7 | >100 |
| Votrient | 5 | - | 5 | - | - | - | - | - | - | - |
| Vaccines | 1,411 | >100 | 171 | 55 | 613 | >100 | 272 | >100 | 355 | >100 |
| Boostrix | 30 | 19 | 15 | 55 | 9 | 25 | 2 | 100 | 4 | (67) |
| Cervarix | 77 | 60 | 2 | - | 59 | 51 | 4 | (33) | 12 | >100 |
| Fluarix, FluLaval | 5 | (43) | 1 | - | - | - | - | (100) | 4 | >100 |
| Flu Pandemic | 698 | >100 | - | - | 304 | >100 | 152 | - | 242 | >100 |
| Hepatitis | 197 | 38 | 92 | 92 | 61 | 2 | 20 | 17 | 24 | 22 |
| Infanrix, Pediarix | 166 | (3) | 32 | (13) | 104 | (2) | 10 | (8) | 20 | 13 |
| Rotarix | 65 | 19 | 27 | 93 | 13 | 8 | 17 | (25) | 8 | 40 |
| Synflorix | 45 | - | - | - | 12 | - | 26 | - | 7 | - |
| Dermatologicals | 265 | >100 | 97 | >100 | 62 | >100 | 62 | 75 | 44 | 95 |
| Bactroban | 27 | (7) | 11 | (20) | 6 | - | 6 | (14) | 4 | 100 |
| Dermovate | 15 | - | - | - | 4 | - | 5 | - | 6 | - |

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

| | | | | | | | | | | |
|-----------------|-------|------|-------|------|-------|------|-----|------|-------|------|
| Duac | 27 | - | 17 | - | 6 | - | 3 | - | 1 | - |
| Soriatane | 18 | - | 18 | - | - | - | - | - | - | - |
| Zovirax | 49 | 61 | 26 | >100 | 7 | (13) | 6 | - | 10 | (17) |
| Other | 211 | 20 | 4 | (20) | 68 | 24 | 80 | 30 | 59 | 11 |
| | 5,753 | 15 | 1,909 | (1) | 1,893 | 16 | 866 | 43 | 1,085 | 35 |
| ViiV Healthcare | | | | | | | | | | |
| (HIV) | 373 | (7) | 159 | (11) | 159 | (3) | 18 | - | 37 | (5) |
| Combivir | 82 | (23) | 34 | (30) | 33 | (17) | 6 | (33) | 9 | - |
| Epivir | 28 | (15) | 10 | (15) | 10 | (21) | 3 | 50 | 5 | (20) |
| Epzicom/Kivexa | 131 | (1) | 48 | (10) | 64 | 6 | 2 | - | 17 | 7 |
| Lexiva | 41 | (8) | 21 | (15) | 15 | (12) | 2 | >100 | 3 | - |
| Selzentry | 19 | - | 8 | - | 11 | - | - | - | - | - |
| Trizivir | 38 | (27) | 19 | (33) | 17 | (29) | 1 | - | 1 | >100 |
| | 6,126 | 14 | | | | | | | | |

Pharmaceuticals turnover

Three months ended 31st December 2009

| | Total | | USA | | Europe | | Emerging Markets | | Rest of World | |
|------------------------|-------|------|-----|------|--------|------|------------------|------|---------------|------|
| | £m | CER% | £m | CER% | £m | CER% | £m | CER% | £m | CER% |
| Respiratory | 1,914 | 7 | 910 | 5 | 594 | 4 | 135 | 17 | 275 | 17 |
| Avamys/Veramyst | 33 | 36 | 15 | (17) | 11 | 83 | 4 | >100 | 3 | - |
| Flixonase/Flonase | 35 | (14) | 6 | (25) | 10 | (17) | 8 | - | 11 | (14) |
| Flixotide/Flovent | 222 | 3 | 115 | 9 | 49 | (4) | 9 | - | 49 | (2) |
| Seretide/Advair | 1,366 | 7 | 704 | 3 | 436 | 7 | 72 | 18 | 154 | 26 |
| Serevent | 61 | (14) | 20 | (9) | 29 | (15) | 1 | - | 11 | (21) |
| Ventolin | 139 | 28 | 48 | 100 | 42 | - | 25 | 9 | 24 | 22 |
| Zyrtec | 22 | 67 | - | - | - | - | 4 | >100 | 18 | 55 |
| Anti-virals | 583 | 20 | 211 | (25) | 88 | 63 | 67 | 48 | 217 | >100 |
| Hepsera | 30 | 7 | - | - | - | - | 13 | 8 | 17 | 7 |
| Relenza | 256 | >100 | 62 | >100 | 39 | >100 | 17 | - | 138 | >100 |
| Valtrex | 222 | (34) | 129 | (45) | 41 | 5 | 8 | 33 | 44 | (9) |
| Zeffix | 55 | - | 4 | - | 7 | (14) | 29 | 12 | 15 | (13) |
| Central nervous system | 504 | (27) | 178 | (50) | 146 | (7) | 50 | 24 | 130 | (3) |
| Imigran/Imitrex | 81 | (50) | 43 | (64) | 25 | (8) | 2 | - | 11 | - |
| Lamictal | 132 | (27) | 72 | (40) | 39 | (5) | 12 | - | 9 | 29 |
| Requip | 65 | 3 | 16 | 27 | 37 | (8) | 1 | - | 11 | 11 |
| Seroxat/Paxil | 139 | (16) | 10 | (47) | 22 | (24) | 19 | 5 | 88 | (10) |
| Treximet | 14 | 15 | 14 | 8 | - | - | - | - | - | - |
| Wellbutrin | 22 | (64) | 10 | (79) | 9 | 33 | 3 | 50 | - | (50) |

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

| | | | | | | | | | | |
|-------------------------------|-------|------|-------|------|-------|------|-----|------|-------|------|
| Cardiovascular and urogenital | 615 | 10 | 375 | 8 | 155 | 8 | 29 | 30 | 56 | 23 |
| Arixtra | 74 | 31 | 43 | 35 | 26 | 14 | 2 | 100 | 3 | 100 |
| Avodart | 143 | 16 | 83 | 11 | 39 | 12 | 6 | 75 | 15 | 50 |
| Coreg | 31 | (46) | 31 | (45) | - | - | - | - | - | - |
| Fraxiparine | 60 | 2 | - | - | 45 | - | 12 | 20 | 3 | (25) |
| Lovaza | 129 | 29 | 128 | 29 | - | - | - | - | 1 | - |
| Vesicare | 29 | 26 | 29 | 26 | - | - | - | - | - | - |
| Volibris | 7 | >100 | - | - | 7 | >100 | - | - | - | - |
| Metabolic | 300 | (15) | 150 | (18) | 69 | (13) | 28 | (13) | 53 | (7) |
| Avandia products | 191 | (17) | 109 | (17) | 40 | (17) | 17 | (23) | 25 | (14) |
| Bonviva/Boniva | 67 | (13) | 41 | (20) | 23 | (4) | 1 | - | 2 | 100 |
| Anti-bacterials | 378 | 3 | 24 | (16) | 176 | (2) | 138 | 18 | 40 | (5) |
| Augmentin | 173 | 7 | 9 | (33) | 82 | 7 | 62 | 23 | 20 | (6) |
| Oncology and emesis | 170 | 17 | 86 | 30 | 52 | - | 15 | 27 | 17 | 15 |
| Arzerra | 3 | - | 3 | - | - | - | - | - | - | - |
| Hycamtin | 45 | 7 | 26 | 4 | 15 | 7 | 1 | 100 | 3 | - |
| Promacta | 5 | - | 5 | - | - | - | - | - | - | - |
| Tyverb/Tykerb | 48 | 29 | 14 | (7) | 21 | 12 | 6 | 50 | 7 | - |
| Votrient | 1 | - | 1 | - | - | - | - | - | - | - |
| Vaccines | 1,523 | 78 | 294 | 55 | 794 | >100 | 229 | 28 | 206 | >100 |
| Boostrix | 35 | 100 | 17 | >100 | 11 | 57 | 1 | - | 6 | >100 |
| Cervarix | 38 | (33) | 4 | - | 19 | (58) | 7 | - | 8 | >100 |
| Fluarix, FluLaval | 42 | (33) | 5 | (64) | 11 | (43) | 14 | - | 12 | 8 |
| Flu Pandemic | 836 | >100 | 162 | >100 | 511 | >100 | 55 | - | 108 | >100 |
| Hepatitis | 151 | (19) | 51 | (27) | 64 | (16) | 18 | (10) | 18 | (6) |
| Infanrix, Pediarix | 153 | (24) | 27 | (50) | 101 | (14) | 9 | (11) | 16 | (6) |
| Rotarix | 70 | 5 | 17 | - | 14 | 8 | 33 | 3 | 6 | 25 |
| Synflorix | 48 | - | - | - | 11 | - | 31 | - | 6 | - |
| Dermatologicals | 255 | >100 | 91 | 29 | 56 | (10) | 57 | 7 | 51 | >100 |
| Bactroban | 28 | (7) | 14 | (8) | 6 | (21) | 6 | 12 | 2 | (3) |
| Dermovate | - | - | - | - | - | - | - | - | - | - |
| Duac | 23 | - | 15 | - | 6 | - | 1 | - | 1 | - |
| Soriatane | 16 | - | 16 | - | - | - | - | - | - | - |
| Zovirax | 38 | (23) | 13 | >100 | 7 | (13) | 5 | - | 13 | (14) |
| Other | 256 | 20 | 3 | 67 | 100 | 14 | 69 | 26 | 84 | 19 |
| | 6,498 | 16 | 2,322 | (4) | 2,230 | 26 | 817 | 22 | 1,129 | 52 |
| ViiV Healthcare (HIV) | 412 | (3) | 189 | (3) | 155 | (10) | 30 | 24 | 38 | 3 |
| Combivir | 109 | (5) | 47 | (9) | 37 | (14) | 15 | 50 | 10 | - |
| Epivir | 30 | (17) | 12 | (7) | 11 | (27) | 2 | 100 | 5 | (33) |

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

| | | | | | | | | | | |
|----------------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|
| Epzicom/Kivexa | 149 | 11 | 63 | 13 | 63 | 5 | 6 | 20 | 17 | 25 |
| Lexiva | 44 | (9) | 25 | (4) | 14 | (7) | 2 | (60) | 3 | 100 |
| Selzentry | 1 | - | - | - | 1 | - | - | - | - | - |
| Trizivir | 49 | (19) | 26 | (19) | 19 | (18) | 3 | 50 | 1 | (67) |
| | ----- | ----- | ----- | ----- | ----- | ----- | ----- | ----- | ----- | ----- |
| | 6,910 | 15 | | | | | | | | |
| | ----- | ----- | | | | | | | | |

Pharmaceuticals turnover

Three months ended 30th September 2009

| | Total | | USA | | Europe | | Emerging Markets of World | | Rest | |
|-------------------------------|-------|------|-----|------|--------|------|---------------------------|------|------|------|
| | £m | CER% | £m | CER% | £m | CER% | £m | CER% | £m | CER% |
| Respiratory | 1,594 | 6 | 744 | 2 | 511 | 7 | 127 | 34 | 212 | 3 |
| Avamys/Veramyst | 31 | 59 | 15 | 8 | 9 | >100 | 3 | - | 4 | - |
| Flixonase/Flonase | 28 | (21) | 3 | (57) | 9 | (18) | 9 | - | 7 | (14) |
| Flixotide/Flovent | 169 | - | 85 | 4 | 38 | (5) | 9 | 33 | 37 | (9) |
| Seretide/Advair | 1,152 | 5 | 587 | (1) | 378 | 9 | 66 | 25 | 121 | 10 |
| Serevent | 54 | (18) | 16 | (18) | 27 | (16) | - | - | 11 | (30) |
| Ventolin | 110 | 28 | 35 | >100 | 35 | 3 | 22 | 29 | 18 | (24) |
| Zyrtec | 18 | >100 | - | - | - | - | 6 | >100 | 12 | 67 |
| Anti-virals | 630 | 38 | 328 | 17 | 85 | 86 | 60 | 55 | 157 | 72 |
| Hepsera | 28 | 25 | - | - | - | - | 12 | 25 | 16 | 17 |
| Relenza | 182 | >100 | 45 | >100 | 38 | - | 13 | - | 86 | >100 |
| Valtrex | 349 | (1) | 265 | 3 | 38 | (3) | 6 | - | 40 | (18) |
| Zeffix | 54 | 14 | 4 | - | 7 | - | 29 | 20 | 14 | 18 |
| Central nervous system | 418 | (37) | 115 | (67) | 139 | (9) | 51 | 30 | 113 | 4 |
| Imigran/Imitrex | 53 | (74) | 19 | (89) | 23 | (8) | 1 | - | 10 | (11) |
| Lamictal | 121 | (21) | 64 | (35) | 38 | (5) | 11 | - | 8 | 60 |
| Requip | 43 | (30) | (4) | - | 34 | (9) | - | - | 13 | 29 |
| Seroxat/Paxil | 120 | (12) | 5 | (54) | 22 | (26) | 19 | 13 | 74 | (2) |
| Treximet | 15 | >100 | 15 | >100 | - | - | - | - | - | - |
| Wellbutrin | 16 | (70) | 4 | (86) | 8 | 33 | 3 | - | 1 | - |
| Cardiovascular and urogenital | 552 | 5 | 336 | 4 | 142 | 2 | 28 | 33 | 46 | 3 |
| Arixtra | 60 | 20 | 32 | 23 | 24 | 11 | 2 | - | 2 | 100 |
| Avodart | 131 | 14 | 80 | 10 | 36 | 10 | 6 | 50 | 9 | 50 |
| Coreg | 39 | (30) | 39 | (31) | - | - | - | - | - | - |
| Fraxiparine | 56 | (12) | - | - | 42 | (15) | 11 | 10 | 3 | (50) |
| Lovaza | 111 | 27 | 111 | 24 | - | - | - | - | - | - |
| Vesicare | 25 | 17 | 25 | 17 | - | - | - | - | - | - |
| Volibris | 6 | >100 | - | - | 5 | >100 | - | - | 1 | - |
| Metabolic | 284 | (13) | 132 | (15) | 67 | (14) | 31 | (9) | 54 | (10) |

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

| | | | | | | | | | | |
|-----------------------|-------|------|-------|------|-------|------|-----|------|-----|------|
| Avandia products | 185 | (14) | 97 | (14) | 42 | (19) | 20 | 12 | 26 | (22) |
| Bonviva/Boniva | 60 | (5) | 35 | (17) | 22 | 11 | - | - | 3 | 50 |
| Anti-bacterials | 340 | 4 | 22 | (15) | 137 | (4) | 138 | 19 | 43 | 1 |
| Augmentin | 162 | 8 | 9 | (22) | 68 | 2 | 68 | 18 | 17 | 13 |
| Oncology and emesis | 149 | 4 | 64 | (11) | 51 | 15 | 16 | 50 | 18 | 8 |
| Arzerra | - | - | - | - | - | - | - | - | - | - |
| Hycamtin | 41 | 9 | 24 | - | 14 | 8 | 2 | - | 1 | >100 |
| Promacta | 3 | - | 3 | - | - | - | - | - | - | - |
| Tyverb/Tykerb | 46 | 54 | 12 | (8) | 19 | 90 | 7 | >100 | 8 | 100 |
| Votrient | - | - | - | - | - | - | - | - | - | - |
| Vaccines | 802 | (2) | 206 | (20) | 344 | (3) | 164 | 30 | 88 | 5 |
| Boostrix | 39 | 55 | 24 | 54 | 11 | 43 | - | - | 4 | 50 |
| Cervarix | 28 | (40) | - | - | 17 | (61) | 6 | >100 | 5 | 100 |
| Fluarix, FluLaval | 147 | (14) | 63 | (20) | 60 | (10) | 14 | 8 | 10 | (25) |
| Flu Pandemic | 11 | - | - | - | 4 | (60) | - | - | 7 | - |
| Hepatitis | 170 | (12) | 67 | (29) | 65 | - | 22 | 31 | 16 | (13) |
| Infanrix, Pediarix | 167 | (10) | 30 | (52) | 105 | 8 | 15 | 40 | 17 | 8 |
| Rotarix | 84 | 92 | 22 | >100 | 14 | 9 | 43 | 100 | 5 | 20 |
| Synflorix | 13 | - | - | - | 11 | - | 1 | - | 1 | - |
| Dermatologicals | 220 | 84 | 74 | (13) | 52 | (6) | 52 | 7 | 42 | >100 |
| Bactroban | 33 | 1 | 15 | (6) | 7 | (4) | 7 | 13 | 4 | 34 |
| Dermovate | - | - | - | - | - | - | - | - | - | - |
| Duac | 23 | - | 15 | - | 4 | - | 2 | - | 2 | - |
| Soriatane | 12 | - | 12 | - | - | - | - | - | - | - |
| Zovirax | 27 | (4) | 4 | - | 7 | (14) | 5 | 20 | 11 | (10) |
| Other | 204 | 20 | 7 | (75) | 70 | 34 | 79 | 45 | 48 | (5) |
| | 5,193 | 3 | 2,028 | (12) | 1,598 | 4 | 746 | 28 | 821 | 24 |
| ViiV Healthcare (HIV) | 395 | (7) | 168 | (5) | 154 | (6) | 33 | (16) | 40 | (3) |
| Combivir | 102 | (15) | 43 | (10) | 36 | (13) | 14 | (29) | 9 | (10) |
| Epivir | 34 | (14) | 12 | (9) | 12 | (15) | 6 | (14) | 4 | (25) |
| Epzicom/Kivexa | 131 | 6 | 52 | 2 | 60 | 10 | 6 | 100 | 13 | (15) |
| Lexiva | 43 | (3) | 24 | - | 15 | (7) | 2 | - | 2 | - |
| Selzentry | - | - | - | - | - | - | - | - | - | - |
| Trizivir | 48 | (12) | 23 | (13) | 19 | (23) | 3 | >100 | 3 | - |
| | 5,588 | 2 | | | | | | | | |

Pharmaceuticals turnover
Three months ended 30th June 2009

Total USA Europe Emerging Markets

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

| | | | | | | | | | Rest of World | |
|-------------------------------|-------|------|-----|------|-----|------|-----|------|---------------|------|
| | £m | CER% | £m | CER% | £m | CER% | £m | CER% | £m | CER% |
| Respiratory | 1,734 | 6 | 825 | 5 | 550 | 2 | 133 | 21 | 226 | 12 |
| Avamys/Veramyst | 47 | >100 | 18 | 7 | 16 | >100 | 3 | - | 10 | >100 |
| Flixonase/Flonase | 39 | (46) | 8 | (82) | 12 | (25) | 10 | 25 | 9 | (13) |
| Flixotide/Flovent | 189 | 1 | 97 | 12 | 43 | (5) | 8 | 33 | 41 | (17) |
| Seretide/Advair | 1,245 | 9 | 648 | 7 | 401 | 3 | 73 | 17 | 123 | 35 |
| Serevent | 59 | (21) | 18 | (13) | 29 | (18) | 1 | - | 11 | (33) |
| Ventolin | 112 | 23 | 32 | >100 | 36 | 3 | 24 | - | 20 | (5) |
| Zyrtec | 17 | 63 | - | - | - | - | 3 | - | 14 | 43 |
| Anti-virals | 537 | 21 | 328 | 21 | 72 | 40 | 52 | 16 | 85 | 10 |
| Hepsera | 29 | 9 | - | - | - | - | 13 | - | 16 | 8 |
| Relenza | 60 | >100 | 19 | >100 | 25 | >100 | 4 | - | 12 | - |
| Valtrex | 379 | 9 | 291 | 16 | 39 | (3) | 6 | 20 | 43 | (20) |
| Zeffix | 55 | (4) | 5 | (25) | 8 | 17 | 29 | 10 | 13 | (25) |
| Central nervous system | 449 | (53) | 142 | (79) | 144 | (8) | 47 | 19 | 116 | (2) |
| Imigran/Imitrex | 68 | (65) | 33 | (79) | 23 | (13) | 1 | - | 11 | - |
| Lamictal | 103 | (73) | 45 | (86) | 38 | (8) | 12 | 10 | 8 | (29) |
| Requip | 51 | (22) | 6 | (78) | 35 | 3 | 1 | - | 9 | - |
| Seroxat/Paxil | 138 | (13) | 13 | (31) | 27 | (19) | 21 | 13 | 77 | (13) |
| Treximet | 12 | 25 | 12 | 25 | - | - | - | - | - | - |
| Wellbutrin | 30 | (72) | 20 | (81) | 7 | 100 | 2 | 50 | 1 | (67) |
| Cardiovascular and urogenital | 580 | 10 | 360 | 12 | 145 | 2 | 27 | 25 | 48 | 15 |
| Arixtra | 61 | 39 | 33 | 63 | 23 | 24 | 2 | 100 | 3 | (50) |
| Avodart | 134 | 21 | 83 | 16 | 37 | 21 | 5 | 67 | 9 | 33 |
| Coreg | 51 | (9) | 50 | (7) | - | - | - | - | 1 | - |
| Fraxiparine | 58 | (9) | - | - | 43 | (15) | 10 | 25 | 5 | - |
| Lovaza | 104 | 22 | 104 | 24 | - | - | - | - | - | - |
| Vesicare | 26 | 31 | 26 | 31 | - | - | - | - | - | - |
| Volibris | 4 | - | - | - | 4 | - | - | - | - | - |
| Metabolic | 303 | (12) | 149 | (17) | 71 | (11) | 32 | 4 | 51 | (9) |
| Avandia products | 198 | (14) | 107 | (19) | 46 | (18) | 21 | 12 | 24 | (4) |
| Bonviva/Boniva | 66 | (2) | 41 | (11) | 23 | 6 | 1 | - | 1 | >100 |
| Anti-bacterials | 346 | 4 | 28 | (1) | 139 | (3) | 137 | 19 | 42 | (10) |
| Augmentin | 146 | 2 | 11 | 13 | 61 | - | 59 | 13 | 15 | (24) |
| Oncology and emesis | 166 | 19 | 88 | 19 | 50 | 12 | 14 | 27 | 14 | 38 |
| Arzerra | - | - | - | - | - | - | - | - | - | - |
| Hycamtin | 43 | 3 | 24 | 5 | 15 | 17 | 2 | - | 2 | - |
| Promacta | 3 | - | 3 | - | - | - | - | - | - | - |
| Tyverb/Tykerb | 41 | 64 | 17 | 18 | 18 | 88 | 6 | >100 | - | - |

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

| | | | | | | | | | | |
|--------------------|-------|------|-------|------|-------|------|-----|------|-----|------|
| Votrient | - | - | - | - | - | - | - | - | - | - |
| Vaccines | 756 | 14 | 196 | 22 | 320 | 7 | 145 | 8 | 95 | 42 |
| Boostrix | 39 | 78 | 21 | 78 | 10 | 14 | 5 | >100 | 3 | >100 |
| Cervarix | 73 | >100 | - | - | 63 | >100 | 4 | >100 | 6 | 100 |
| Fluarix, FluLaval | 14 | >100 | 3 | - | - | - | 9 | 33 | 2 | - |
| Flu Pandemic | 30 | (26) | 25 | - | 5 | (86) | - | - | - | - |
| Hepatitis | 195 | (2) | 87 | 2 | 72 | (8) | 22 | (6) | 14 | 27 |
| Infanrix, Pediarix | 154 | (20) | 38 | (43) | 91 | (13) | 9 | - | 16 | (6) |
| Rotarix | 71 | 69 | 22 | - | 12 | 20 | 29 | 14 | 8 | 50 |
| Synflorix | 12 | - | - | - | 10 | - | - | - | 2 | - |
| Dermatologicals | 120 | (2) | 22 | (9) | 31 | (3) | 38 | 5 | 29 | (5) |
| Bactroban | 32 | - | 15 | (6) | 7 | (5) | 7 | 24 | 3 | (3) |
| Dermovate | - | - | - | - | - | - | - | - | - | - |
| Duac | - | - | - | - | - | - | - | - | - | - |
| Soriatane | - | - | - | - | - | - | - | - | - | - |
| Zovirax | 33 | (4) | 4 | 33 | 8 | - | 7 | - | 14 | (17) |
| Other | 208 | (1) | 2 | >100 | 66 | 1 | 68 | 8 | 72 | (18) |
| | 5,199 | (3) | 2,140 | (15) | 1,588 | 2 | 693 | 14 | 778 | 7 |
| ViiV Healthcare | | | | | | | | | | |
| (HIV) | 379 | (10) | 164 | (8) | 155 | (14) | 24 | (4) | 36 | (6) |
| Combivir | 102 | (17) | 44 | (15) | 37 | (25) | 11 | (8) | 10 | - |
| Epivir | 31 | (24) | 11 | (18) | 12 | (33) | 3 | (50) | 5 | 25 |
| Epzicom/Kivexa | 129 | 6 | 50 | - | 59 | - | 5 | 100 | 15 | 44 |
| Lexiva | 43 | (8) | 23 | 6 | 16 | (13) | 2 | 100 | 2 | - |
| Selzentry | - | - | - | - | - | - | - | - | - | - |
| Trizivir | 48 | (18) | 25 | (13) | 20 | (25) | 1 | - | 2 | - |
| | 5,578 | (4) | | | | | | | | |

Pharmaceuticals turnover

Three months ended 31st March 2009

| | Total | | USA | | Europe | | Emerging Markets | | Rest of World | |
|-------------------|-------|------|-----|------|--------|------|------------------|------|---------------|------|
| | £m | CER% | £m | CER% | £m | CER% | £m | CER% | £m | CER% |
| Respiratory | 1,735 | 1 | 844 | (1) | 546 | (1) | 115 | 16 | 230 | 6 |
| Avamys/Veramyst | 31 | 85 | 20 | 17 | 9 | >100 | 1 | - | 1 | - |
| Flixonase/Flonase | 69 | 11 | 10 | 100 | 12 | (23) | 8 | - | 39 | 17 |
| Flixotide/Flovent | 195 | (6) | 99 | (4) | 48 | (2) | 8 | - | 40 | (14) |
| Seretide/Advair | 1,214 | - | 653 | (5) | 394 | - | 65 | 27 | 102 | 26 |
| Serevent | 62 | (24) | 19 | (18) | 31 | (22) | 1 | - | 11 | (42) |
| Ventolin | 116 | 23 | 38 | >100 | 37 | (3) | 22 | 6 | 19 | (16) |
| Zyrtec | 18 | 9 | - | - | - | - | 1 | - | 17 | 10 |

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

| | | | | | | | | | | |
|-------------------------------|-----|------|-----|------|-----|------|-----|------|-----|------|
| Anti-virals | 666 | 44 | 288 | 7 | 163 | >100 | 47 | (3) | 168 | 43 |
| Hepsera | 27 | 5 | - | - | - | - | 13 | - | 14 | 1 |
| Relenza | 222 | >100 | 11 | - | 110 | - | - | - | 101 | >100 |
| Valtrex | 344 | 2 | 257 | 8 | 42 | - | 6 | - | 39 | (19) |
| Zeffix | 53 | (13) | 4 | - | 7 | (14) | 28 | (13) | 14 | (15) |
| Central nervous system | 499 | (53) | 216 | (73) | 145 | (2) | 42 | 6 | 96 | (7) |
| Imigran/Imitrex | 64 | (68) | 28 | (83) | 25 | (4) | 1 | - | 10 | - |
| Lamictal | 144 | (61) | 86 | (74) | 39 | 3 | 13 | 22 | 6 | (25) |
| Requip | 50 | (56) | 8 | (90) | 32 | (3) | - | - | 10 | 40 |
| Seroxat/Paxil | 126 | (21) | 14 | (61) | 28 | (14) | 17 | - | 67 | (4) |
| Treximet | 14 | - | 14 | - | - | - | - | - | - | - |
| Wellbutrin | 64 | (63) | 54 | (68) | 6 | 67 | 2 | - | 2 | - |
| Cardiovascular and urogenital | 551 | 6 | 344 | 7 | 141 | 2 | 24 | 25 | 42 | 3 |
| Arixtra | 59 | 29 | 33 | 26 | 22 | 29 | 1 | - | 3 | - |
| Avodart | 122 | 12 | 73 | 8 | 36 | 7 | 5 | 33 | 8 | 60 |
| Coreg | 51 | (23) | 51 | (23) | - | - | - | - | - | - |
| Fraxiparine | 55 | (8) | - | - | 43 | (10) | 9 | - | 3 | - |
| Lovaza | 106 | 54 | 105 | 52 | - | - | - | - | 1 | - |
| Vesicare | 24 | 21 | 24 | 21 | - | - | - | - | - | - |
| Volibris | 2 | - | - | - | 2 | - | - | - | - | - |
| Metabolic | 294 | (16) | 150 | (18) | 68 | (21) | 28 | 9 | 48 | (16) |
| Avandia products | 197 | (19) | 112 | (18) | 43 | (30) | 18 | 8 | 24 | (16) |
| Bonviva/Boniva | 62 | (4) | 38 | (15) | 21 | 20 | - | - | 3 | - |
| Anti-bacterials | 393 | (1) | 29 | (30) | 183 | (7) | 141 | 20 | 40 | (8) |
| Augmentin | 186 | - | 16 | (29) | 84 | (9) | 67 | 29 | 19 | (7) |
| Oncology and emesis | 144 | 1 | 70 | (12) | 51 | 16 | 12 | 25 | 11 | - |
| Arzerra | - | - | - | - | - | - | - | - | - | - |
| Hycamtin | 43 | 10 | 26 | 6 | 15 | 9 | 1 | - | 1 | - |
| Promacta | 2 | - | 2 | - | - | - | - | - | - | - |
| Tyverb/Tykerb | 34 | 42 | 11 | (20) | 17 | >100 | 3 | >100 | 3 | - |
| Votrient | - | - | - | - | - | - | - | - | - | - |
| Vaccines | 625 | 18 | 119 | (21) | 286 | 23 | 131 | 75 | 89 | 18 |
| Boostrix | 26 | 62 | 11 | 60 | 8 | 40 | 1 | - | 6 | 67 |
| Cervarix | 48 | >100 | - | - | 39 | >100 | 6 | >100 | 3 | >100 |
| Fluarix, FluLaval | 6 | - | - | - | - | - | 5 | - | 1 | - |
| Flu Pandemic | 6 | 20 | - | - | 5 | 25 | - | - | 1 | - |
| Hepatitis | 149 | (12) | 52 | (28) | 61 | (5) | 18 | 25 | 18 | (11) |
| Infanrix, Pediarix | 175 | (5) | 39 | (41) | 109 | 14 | 12 | 43 | 15 | - |
| Rotarix | 57 | 74 | 15 | - | 13 | 22 | 24 | 40 | 5 | 33 |
| Synflorix | - | - | - | - | - | - | - | - | - | - |
| Dermatologicals | 112 | (1) | 23 | 15 | 31 | (6) | 36 | 2 | 22 | (13) |

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

| | | | | | | | | | | |
|-----------------|-------|------|-------|------|-------|------|-----|------|-----|------|
| Bactroban | 30 | (5) | 15 | (14) | 6 | (5) | 7 | 21 | 2 | (11) |
| Dermovate | - | - | - | - | - | - | - | - | - | - |
| Duac | - | - | - | - | - | - | - | - | - | - |
| Soriatane | - | - | - | - | - | - | - | - | - | - |
| Zovirax | 31 | 4 | 5 | >100 | 8 | (13) | 6 | - | 12 | (18) |
| Other | 180 | (29) | 5 | - | 55 | (8) | 63 | 2 | 57 | (59) |
| | 5,199 | (6) | 2,088 | (24) | 1,669 | 9 | 639 | 20 | 803 | (3) |
| ViiV Healthcare | | | | | | | | | | |
| (HIV) | 419 | (8) | 195 | (8) | 169 | (9) | 19 | (24) | 36 | 7 |
| Combivir | 112 | (16) | 53 | (16) | 41 | (17) | 9 | (20) | 9 | (13) |
| Epivir | 34 | (21) | 13 | (18) | 14 | (20) | 2 | (33) | 5 | (20) |
| Epzicom/Kivexa | 137 | 10 | 58 | 5 | 62 | 10 | 3 | >100 | 14 | 10 |
| Lexiva | 48 | 6 | 27 | 6 | 17 | (7) | 1 | - | 3 | >100 |
| Selzentry | - | - | - | - | - | - | - | - | - | - |
| Trizivir | 56 | (20) | 30 | (22) | 24 | (17) | 1 | - | 1 | (50) |
| | 5,618 | (6) | | | | | | | | |

Pharmaceuticals turnover
Three months ended 31st December 2008

| | Total | | USA | | Europe | | Emerging Markets | | Rest of World | |
|------------------------|-------|------|-----|------|--------|------|------------------|------|---------------|------|
| | £m | CER% | £m | CER% | £m | CER% | £m | CER% | £m | CER% |
| Respiratory | 1,731 | 7 | 852 | 9 | 550 | 3 | 116 | 19 | 213 | 1 |
| Avamys/Veramyst | 25 | >100 | 18 | 75 | 6 | - | 1 | - | - | - |
| Flixonase/Flonase | 42 | 9 | 8 | >100 | 12 | (17) | 8 | 14 | 14 | (17) |
| Flixotide/Flovent | 208 | (1) | 103 | 2 | 50 | 2 | 9 | 14 | 46 | (14) |
| Seretide/Advair | 1,237 | 8 | 674 | 6 | 392 | 5 | 62 | 22 | 109 | 36 |
| Serevent | 70 | (18) | 22 | (5) | 33 | (17) | 1 | 100 | 14 | (44) |
| Ventolin | 104 | 12 | 23 | >100 | 40 | 9 | 23 | 5 | 18 | (32) |
| Zyrtec | 12 | (7) | - | - | - | - | 1 | - | 11 | (11) |
| Anti-virals | 476 | (4) | 303 | 4 | 51 | 7 | 46 | 19 | 76 | (37) |
| Hepsera | 27 | 20 | - | - | - | - | 12 | 25 | 15 | 8 |
| Relenza | 13 | (85) | 5 | (93) | 5 | 25 | - | - | 3 | (90) |
| Valtrex | 366 | 16 | 279 | 24 | 38 | 3 | 6 | 75 | 43 | (18) |
| Zeffix | 53 | 2 | 4 | 33 | 7 | (17) | 26 | 17 | 16 | (13) |
| Central nervous system | 665 | (43) | 353 | (61) | 151 | - | 41 | 6 | 120 | (5) |
| Imigran/Imitrex | 161 | (34) | 123 | (40) | 25 | (4) | 1 | - | 12 | (22) |
| Lamictal | 177 | (57) | 119 | (68) | 39 | (8) | 12 | 11 | 7 | (14) |
| Requip | 58 | (53) | 11 | (92) | 38 | 28 | - | - | 9 | 33 |
| Seroxat/Paxil | 154 | (21) | 19 | (67) | 29 | (10) | 19 | 7 | 87 | (4) |

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

| | | | | | | | | | | |
|-------------------------------|-------|------|-------|------|-------|------|-----|------|-----|------|
| Treximet | 13 | - | 13 | - | - | - | - | - | - | - |
| Wellbutrin | 66 | (63) | 56 | (69) | 6 | >100 | 2 | - | 2 | - |
| Cardiovascular and urogenital | 548 | 51 | 344 | >100 | 137 | 5 | 23 | 31 | 44 | 8 |
| Arixtra | 55 | 59 | 31 | 63 | 21 | 64 | 1 | - | 2 | (50) |
| Avodart | 120 | 19 | 75 | 22 | 33 | 12 | 4 | 100 | 8 | - |
| Coreg | 61 | >100 | 60 | >100 | - | - | - | - | - | - |
| Fraxiparine | 58 | (2) | - | - | 44 | (10) | 10 | 50 | 4 | - |
| Lovaza | 98 | >100 | 98 | >100 | - | - | - | - | - | - |
| Vesicare | 23 | 36 | 23 | 36 | - | - | - | - | - | - |
| Volibris | 1 | - | - | - | 1 | - | - | - | - | - |
| Metabolic | 345 | (11) | 182 | (13) | 76 | (16) | 32 | 4 | 55 | (6) |
| Avandia products | 229 | (17) | 132 | (21) | 47 | (27) | 22 | 11 | 28 | - |
| Bonviva/Boniva | 76 | 23 | 51 | 8 | 23 | 33 | 1 | - | 1 | - |
| Anti-bacterials | 361 | (7) | 31 | (27) | 172 | (9) | 120 | 5 | 38 | (14) |
| Augmentin | 159 | (5) | 15 | (13) | 74 | (6) | 52 | - | 18 | (7) |
| Oncology and emesis | 138 | 12 | 64 | 11 | 50 | 16 | 11 | 25 | 13 | (10) |
| Arzerra | - | - | - | - | - | - | - | - | - | - |
| Hycamtin | 41 | 10 | 25 | 18 | 14 | - | 1 | 100 | 1 | (50) |
| Promacta | - | - | - | - | - | - | - | - | - | - |
| Tyverb/Tykerb | 35 | 58 | 14 | (8) | 17 | >100 | 4 | >100 | - | - |
| Votrient | - | - | - | - | - | - | - | - | - | - |
| Vaccines | 796 | 8 | 178 | (31) | 356 | 23 | 172 | 51 | 90 | 8 |
| Boostrix | 17 | - | 8 | - | 7 | 20 | - | - | 2 | (50) |
| Cervarix | 55 | >100 | - | - | 45 | >100 | 7 | - | 3 | - |
| Fluarix, FluLaval | 66 | 12 | 22 | (27) | 21 | 89 | 13 | >100 | 10 | (21) |
| Flu Pandemic | 17 | (86) | 1 | (99) | 15 | (68) | - | - | 1 | - |
| Hepatitis | 185 | 5 | 74 | 6 | 74 | - | 20 | 21 | 17 | 13 |
| Infanrix, Pediarix | 194 | 19 | 56 | - | 113 | 36 | 9 | (11) | 16 | 9 |
| Rotarix | 66 | 59 | 17 | - | 13 | 57 | 32 | - | 4 | >100 |
| Synflorix | - | - | - | - | - | - | - | - | - | - |
| Dermatologicals | 113 | (2) | 23 | (5) | 30 | (8) | 31 | 7 | 29 | - |
| Bactroban | 31 | (7) | 15 | (20) | 7 | (14) | 5 | - | 4 | >100 |
| Dermovate | - | - | - | - | - | - | - | - | - | - |
| Duac | - | - | - | - | - | - | - | - | - | - |
| Soriatane | - | - | - | - | - | - | - | - | - | - |
| Zovirax | 31 | (4) | 4 | 67 | 8 | (13) | 5 | - | 14 | (17) |
| Other | 213 | (14) | 3 | (94) | 88 | 28 | 60 | (5) | 62 | (19) |
| | 5,386 | (4) | 2,333 | (14) | 1,661 | 6 | 652 | 18 | 740 | (8) |
| ViiV Healthcare (HIV) | 417 | (3) | 193 | (1) | 165 | (10) | 25 | 10 | 34 | 7 |
| Combivir | 114 | (13) | 53 | (4) | 42 | (18) | 10 | - | 9 | (40) |

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

| | | | | | | | | | | |
|----------------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|
| Epivir | 36 | (22) | 14 | (15) | 15 | (20) | 1 | (33) | 6 | (33) |
| Epzicom/Kivexa | 129 | 20 | 55 | 19 | 57 | 16 | 5 | >100 | 12 | 11 |
| Lexiva | 47 | 6 | 26 | 11 | 15 | (7) | 5 | >100 | 1 | - |
| Selzentry | - | - | - | - | - | - | - | - | - | - |
| Trizivir | 59 | (14) | 32 | (11) | 22 | (24) | 2 | 100 | 3 | - |
| | ----- | ----- | ----- | ----- | ----- | ----- | ----- | ----- | ----- | ----- |
| | 5,803 | (4) | | | | | | | | |
| | ----- | ----- | | | | | | | | |

Pharmaceuticals turnover

Three months ended 30th September 2008

| | Total | | USA | | Europe | | Emerging Markets | | Rest of World | |
|-------------------------------|-------|------|-----|------|--------|------|------------------|------|---------------|------|
| | £m | CER% | £m | CER% | £m | CER% | £m | CER% | £m | CER% |
| Respiratory | 1,348 | 3 | 636 | 3 | 449 | - | 92 | 11 | 171 | 11 |
| Avamys/Veramyst | 17 | >100 | 12 | >100 | 3 | - | - | - | 2 | - |
| Flixonase/Flonase | 33 | (39) | 7 | (67) | 11 | 11 | 8 | 17 | 7 | (54) |
| Flixotide/Flovent | 149 | (4) | 71 | (1) | 38 | (3) | 6 | 20 | 34 | (12) |
| Seretide/Advair | 982 | 7 | 515 | 5 | 324 | 1 | 51 | 18 | 92 | 46 |
| Serevent | 60 | (14) | 17 | (11) | 32 | (13) | 1 | - | 10 | (9) |
| Ventolin | 78 | 6 | 9 | 60 | 31 | - | 17 | - | 21 | 6 |
| Zyrtec | 7 | (15) | - | - | - | - | 1 | - | 6 | (20) |
| Anti-virals | 391 | 9 | 242 | 20 | 42 | (26) | 33 | - | 74 | 10 |
| Hepsera | 20 | 6 | - | - | - | - | 8 | 17 | 12 | - |
| Relenza | 12 | (57) | 5 | (58) | - | - | - | - | 7 | >100 |
| Valtrex | 303 | 21 | 223 | 28 | 35 | 7 | 6 | - | 39 | 3 |
| Zeffix | 42 | (10) | 4 | (25) | 7 | - | 20 | (11) | 11 | (7) |
| Central nervous system | 585 | (38) | 321 | (52) | 142 | 4 | 37 | 6 | 85 | (10) |
| Imigran/Imitrex | 188 | 5 | 154 | 8 | 24 | (5) | 1 | - | 9 | - |
| Lamictal | 136 | (59) | 84 | (71) | 37 | (9) | 10 | 13 | 5 | (13) |
| Requip | 56 | (43) | 13 | (81) | 35 | 35 | 1 | - | 7 | 40 |
| Seroxat/Paxil | 112 | (23) | 13 | (67) | 27 | (8) | 16 | 8 | 56 | (13) |
| Treximet | 4 | - | 4 | - | - | - | - | - | - | - |
| Wellbutrin | 53 | (67) | 44 | (72) | 6 | 100 | 2 | - | 1 | - |
| Cardiovascular and urogenital | 466 | 12 | 280 | 9 | 130 | 17 | 21 | 36 | 35 | 3 |
| Arixtra | 44 | 56 | 22 | 43 | 19 | 78 | 1 | - | 2 | 100 |
| Avodart | 102 | 29 | 63 | 29 | 29 | 19 | 4 | 50 | 6 | 75 |
| Coreg | 50 | (69) | 49 | (69) | - | - | - | - | 1 | - |
| Fraxiparine | 59 | 22 | - | - | 47 | 18 | 10 | 50 | 2 | - |
| Lovaza | 75 | - | 75 | - | - | - | - | - | - | - |
| Vesicare | 18 | 31 | 18 | 31 | - | - | - | - | - | - |
| Volibris | 1 | - | - | - | 1 | - | - | - | - | - |

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

| | | | | | | | | | | |
|---------------------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|
| Metabolic | 289 | (11) | 136 | (22) | 72 | (2) | 33 | 35 | 48 | (10) |
| Avandia products | 191 | (23) | 99 | (28) | 48 | (16) | 17 | 7 | 27 | (26) |
| Bonviva/Boniva | 56 | 24 | 36 | 18 | 18 | 60 | - | - | 2 | - |
| Anti-bacterials | 306 | 1 | 21 | (19) | 133 | (3) | 114 | 11 | 38 | 3 |
| Augmentin | 143 | 10 | 9 | (36) | 62 | 6 | 56 | 26 | 16 | 15 |
| Oncology and emesis | 128 | 12 | 64 | 13 | 41 | 6 | 10 | - | 13 | 30 |
| Arzerra | - | - | - | - | - | - | - | - | - | - |
| Hycamtin | 34 | 3 | 20 | - | 12 | 10 | 1 | - | 1 | - |
| Promacta | - | - | - | - | - | - | - | - | - | - |
| Tyverb/Tykerb | 26 | 44 | 12 | - | 10 | 80 | 2 | - | 2 | - |
| Votrient | - | - | - | - | - | - | - | - | - | - |
| Vaccines | 730 | 12 | 218 | (13) | 323 | 40 | 114 | 10 | 75 | (11) |
| Boostrix | 22 | (19) | 13 | (40) | 7 | 40 | - | - | 2 | 100 |
| Cervarix | 43 | >100 | - | - | 38 | - | 2 | - | 3 | >100 |
| Fluarix, FluLaval | 144 | 11 | 63 | (19) | 58 | 55 | 12 | 100 | 11 | 100 |
| Flu Pandemic | 10 | (52) | - | - | 10 | >100 | - | - | - | - |
| Hepatitis | 174 | 11 | 82 | 17 | 61 | 2 | 16 | 40 | 15 | - |
| Infanrix, Pediarix | 168 | 9 | 56 | (10) | 89 | 23 | 10 | 14 | 13 | 36 |
| Rotarix | 39 | 57 | 4 | - | 11 | 67 | 19 | 29 | 5 | 33 |
| Synflorix | - | - | - | - | - | - | - | - | - | - |
| Dermatologicals | 102 | 2 | 22 | (5) | 30 | 4 | 32 | 7 | 18 | (10) |
| Bactroban | 29 | 8 | 14 | (8) | 7 | 40 | 6 | 50 | 2 | (50) |
| Dermovate | - | - | - | - | - | - | - | - | - | - |
| Duac | - | - | - | - | - | - | - | - | - | - |
| Soriatane | - | - | - | - | - | - | - | - | - | - |
| Zovirax | 25 | (19) | 3 | (50) | 7 | (29) | 5 | - | 10 | (9) |
| Other | 166 | (5) | 8 | - | 51 | (10) | 52 | (15) | 55 | (17) |
| | ----- | ----- | ----- | ----- | ----- | ----- | ----- | ----- | ----- | ----- |
| | 4,511 | (4) | 1,948 | (13) | 1,413 | 7 | 538 | 8 | 612 | (1) |
| | | | ----- | ----- | ----- | ----- | ----- | ----- | ----- | ----- |
| ViiV Healthcare | | | | | | | | | | |
| (HIV) | 377 | (5) | 153 | (11) | 150 | (6) | 43 | 21 | 31 | - |
| Combivir | 110 | (13) | 41 | (26) | 38 | (19) | 21 | 40 | 10 | - |
| Eпивir | 35 | (16) | 11 | (29) | 13 | (27) | 7 | 20 | 4 | 25 |
| Epzicom/Kivexa | 110 | 24 | 44 | 21 | 50 | 19 | 3 | >100 | 13 | 38 |
| Lexiva | 40 | (3) | 21 | (5) | 15 | (8) | 2 | - | 2 | 50 |
| Selzentry | - | - | - | - | - | - | - | - | - | - |
| Trizivir | 49 | (20) | 24 | (21) | 22 | (17) | 1 | (67) | 2 | 100 |
| | ----- | ----- | ----- | ----- | ----- | ----- | ----- | ----- | ----- | ----- |
| | 4,888 | (4) | | | | | | | | |

Pharmaceuticals turnover
Three months ended 30th June 2008

Total USA Europe Emerging Markets

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

| | | | | | | | Rest of World | | | |
|-------------------------------|-------|------|-----|------|-----|------|---------------|------|-----|------|
| | £m | CER% | £m | CER% | £m | CER% | £m | CER% | £m | CER% |
| Respiratory | 1,383 | 4 | 616 | 4 | 497 | - | 100 | 22 | 170 | 1 |
| Avamys/Veramyst | 17 | 89 | 14 | 56 | 1 | - | - | - | 2 | - |
| Flixonase/Flonase | 65 | 13 | 33 | 32 | 16 | (13) | 8 | - | 8 | 13 |
| Flixotide/Flovent | 158 | (3) | 68 | 5 | 43 | (7) | 6 | (14) | 41 | (10) |
| Seretide/Advair | 964 | 6 | 473 | 2 | 356 | 6 | 58 | 46 | 77 | 9 |
| Serevent | 66 | (11) | 16 | (11) | 34 | (11) | 1 | (50) | 15 | (13) |
| Ventolin | 80 | 6 | 7 | 40 | 33 | (3) | 21 | 12 | 19 | 6 |
| Zyrtec | 8 | (10) | - | - | - | - | 1 | - | 7 | (14) |
| Anti-virals | 361 | (5) | 210 | 2 | 47 | (37) | 37 | 6 | 67 | - |
| Hepsera | 22 | 25 | - | - | - | - | 9 | 29 | 13 | 30 |
| Relenza | 3 | (97) | 2 | (94) | 1 | (96) | - | - | - | - |
| Valtrex | 277 | 19 | 195 | 22 | 36 | 10 | 5 | - | 41 | 16 |
| Zeffix | 47 | - | 4 | 33 | 6 | 20 | 21 | - | 16 | (13) |
| Central nervous system | 818 | (4) | 547 | (6) | 143 | 1 | 36 | 3 | 92 | (1) |
| Imigran/Imitrex | 173 | 2 | 139 | 2 | 24 | - | 1 | - | 9 | - |
| Lamictal | 323 | 18 | 268 | 22 | 38 | (3) | 10 | 25 | 7 | (38) |
| Requip | 58 | (37) | 18 | (69) | 31 | 27 | 1 | - | 8 | >100 |
| Seroxat/Paxil | 127 | (18) | 16 | (47) | 31 | (13) | 16 | (6) | 64 | (7) |
| Treximet | 8 | - | 8 | - | - | - | - | - | - | - |
| Wellbutrin | 97 | (27) | 89 | (30) | 3 | - | 2 | 100 | 3 | (33) |
| Cardiovascular and urogenital | 435 | (5) | 251 | (14) | 129 | 12 | 20 | 36 | 35 | 6 |
| Arixtra | 36 | 31 | 16 | 21 | 17 | 50 | 1 | - | 2 | (50) |
| Avodart | 92 | 33 | 55 | 38 | 28 | 19 | 3 | 100 | 6 | 25 |
| Coreg | 44 | (78) | 43 | (78) | - | - | - | - | 1 | - |
| Fraxiparine | 58 | 13 | - | - | 46 | 3 | 8 | 17 | 4 | >100 |
| Lovaza | 67 | - | 66 | - | - | - | - | - | 1 | - |
| Vesicare | 16 | 25 | 16 | 25 | - | - | - | - | - | - |
| Volibris | - | - | - | - | - | - | - | - | - | - |
| Metabolic | 285 | (35) | 139 | (44) | 73 | (19) | 27 | (17) | 46 | (27) |
| Avandia products | 194 | (46) | 104 | (54) | 49 | (31) | 17 | (24) | 24 | (39) |
| Bonviva/Boniva | 56 | 47 | 36 | 38 | 18 | 60 | 1 | - | 1 | - |
| Anti-bacterials | 298 | (1) | 22 | (31) | 133 | (3) | 104 | 11 | 39 | - |
| Augmentin | 129 | (1) | 8 | (47) | 57 | - | 48 | 13 | 16 | 15 |
| Oncology and emesis | 117 | (11) | 57 | (24) | 41 | 6 | 11 | 38 | 8 | (11) |
| Arzerra | - | - | - | - | - | - | - | - | - | - |
| Hycamtin | 35 | 18 | 19 | 19 | 12 | - | 2 | - | 2 | >100 |
| Promacta | - | - | - | - | - | - | - | - | - | - |
| Tyverb/Tykerb | 22 | 75 | 11 | 20 | 8 | >100 | 2 | - | 1 | - |

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

| | | | | | | | | | | |
|--------------------|-------|------|-------|------|-------|------|-----|------|-----|------|
| Votrient | - | - | - | - | - | - | - | - | - | - |
| Vaccines | 577 | 34 | 124 | 19 | 276 | 41 | 115 | 67 | 62 | - |
| Boostrix | 18 | 21 | 9 | 29 | 7 | 20 | 1 | - | 1 | (50) |
| Cervarix | 15 | - | - | - | 11 | - | 2 | - | 2 | - |
| Fluarix, FluLaval | 5 | 25 | - | - | (1) | - | 6 | 25 | - | - |
| Flu Pandemic | 34 | - | - | - | 35 | - | - | - | (1) | - |
| Hepatitis | 167 | 23 | 66 | 43 | 72 | 3 | 18 | 70 | 11 | 8 |
| Infanrix, Pediarix | 167 | 13 | 49 | (4) | 94 | 26 | 8 | 14 | 16 | 17 |
| Rotarix | 35 | >100 | - | - | 10 | 33 | 21 | >100 | 4 | - |
| Synflorix | - | - | - | - | - | - | - | - | - | - |
| Dermatologicals | 105 | 2 | 20 | 11 | 30 | 4 | 32 | 14 | 23 | (17) |
| Bactroban | 27 | 4 | 13 | 8 | 7 | 20 | 5 | - | 2 | (33) |
| Dermovate | - | - | - | - | - | - | - | - | - | - |
| Duac | - | - | - | - | - | - | - | - | - | - |
| Soriatane | - | - | - | - | - | - | - | - | - | - |
| Zovirax | 28 | - | 3 | >100 | 7 | - | 6 | - | 12 | (15) |
| Other | 183 | (8) | 1 | (67) | 65 | 25 | 57 | (3) | 60 | (28) |
| | 4,562 | (1) | 1,987 | (8) | 1,434 | 6 | 539 | 17 | 602 | (6) |
| ViiV Healthcare | | | | | | | | | | |
| (HIV) | 361 | (6) | 142 | (10) | 164 | (2) | 24 | (20) | 31 | 4 |
| Combivir | 104 | (15) | 41 | (18) | 44 | (19) | 12 | (15) | 7 | 13 |
| Epivir | 34 | (20) | 11 | (8) | 15 | (19) | 4 | (33) | 4 | (33) |
| Epzicom/Kivexa | 104 | 24 | 39 | 6 | 54 | 33 | 2 | 100 | 9 | 67 |
| Lexiva | 38 | 9 | 18 | - | 16 | 8 | 1 | - | 3 | - |
| Selzentry | - | - | - | - | - | - | - | - | - | - |
| Trizivir | 50 | (23) | 23 | (25) | 24 | (13) | 1 | (50) | 2 | (67) |
| | 4,923 | (2) | | | | | | | | |

Pharmaceuticals turnover

Three months ended 31st March 2008

| | Total | | USA | | Europe | | Emerging Markets | | Rest of World | |
|-------------------|-------|------|-----|------|--------|------|------------------|------|---------------|------|
| | £m | CER% | £m | CER% | £m | CER% | £m | CER% | £m | CER% |
| Respiratory | 1,355 | 6 | 616 | 8 | 486 | 4 | 85 | 10 | 168 | 4 |
| Avamys/Veramyst | 13 | - | 12 | - | 1 | - | - | - | - | - |
| Flixonase/Flonase | 46 | (33) | 4 | (84) | 13 | - | 6 | 20 | 23 | (5) |
| Flixotide/Flovent | 162 | (1) | 75 | 7 | 44 | (7) | 7 | 20 | 36 | (11) |
| Seretide/Advair | 954 | 10 | 499 | 10 | 345 | 8 | 44 | 17 | 66 | 20 |
| Serevent | 67 | (5) | 17 | (11) | 37 | 6 | 1 | - | 12 | (23) |
| Ventolin | 77 | 9 | 7 | >100 | 33 | - | 18 | - | 19 | 13 |
| Zyrtec | 11 | 1 | - | - | - | - | 1 | - | 10 | - |

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

| | | | | | | | | | | |
|-------------------------------|-----|------|-----|------|-----|------|-----|------|----|------|
| Anti-virals | 356 | (9) | 194 | (10) | 44 | (40) | 36 | 30 | 82 | 6 |
| Hepsera | 20 | 20 | - | - | - | - | 9 | 33 | 11 | 10 |
| Relenza | 29 | (71) | 8 | (82) | - | - | - | - | 21 | 19 |
| Valtrex | 249 | 9 | 173 | 7 | 35 | 15 | 5 | 67 | 36 | 7 |
| Zeffix | 46 | 8 | 3 | - | 7 | - | 23 | 24 | 13 | (7) |
| Central nervous system | 829 | 3 | 594 | 7 | 129 | (8) | 33 | 3 | 73 | (11) |
| Imigran/Imitrex | 165 | (1) | 134 | - | 23 | (5) | 1 | - | 7 | (13) |
| Lamictal | 290 | 16 | 240 | 22 | 33 | (14) | 9 | 13 | 8 | - |
| Requip | 94 | 15 | 60 | 9 | 29 | 24 | - | - | 5 | 67 |
| Seroxat/Paxil | 121 | (15) | 31 | (16) | 28 | (24) | 14 | - | 48 | (12) |
| Treximet | - | - | - | - | - | - | - | - | - | - |
| Wellbutrin | 126 | (3) | 121 | (4) | 3 | >100 | 1 | (50) | 1 | - |
| Cardiovascular and urogenital | 398 | (12) | 232 | (22) | 116 | 6 | 16 | 7 | 34 | 24 |
| Arixtra | 35 | 70 | 19 | 73 | 14 | 33 | - | - | 2 | - |
| Avodart | 85 | 30 | 49 | 22 | 28 | 39 | 3 | 100 | 5 | 67 |
| Coreg | 48 | (77) | 48 | (78) | - | - | - | - | - | (50) |
| Fraxiparine | 51 | (4) | - | - | 41 | (8) | 7 | 17 | 3 | - |
| Lovaza | 50 | - | 50 | - | - | - | - | - | - | - |
| Vesicare | 14 | 36 | 14 | 36 | - | - | - | - | - | - |
| Volibris | - | - | - | - | - | - | - | - | - | - |
| Metabolic | 272 | (45) | 133 | (57) | 73 | (6) | 22 | (28) | 44 | (31) |
| Avandia products | 191 | (56) | 99 | (66) | 54 | (14) | 13 | (43) | 25 | (45) |
| Bonviva/Boniva | 49 | 50 | 33 | 48 | 15 | 44 | - | - | 1 | - |
| Anti-bacterials | 336 | (4) | 30 | (26) | 169 | (8) | 100 | 16 | 37 | (3) |
| Augmentin | 156 | (1) | 17 | (29) | 79 | - | 45 | 19 | 15 | (13) |
| Oncology and emesis | 113 | (27) | 58 | (41) | 37 | 6 | 8 | 17 | 10 | (10) |
| Arzerra | - | - | - | - | - | - | - | - | - | - |
| Hycamtin | 30 | (3) | 17 | (5) | 11 | 11 | 1 | - | 1 | - |
| Promacta | - | - | - | - | - | - | - | - | - | - |
| Tyverb/Tykerb | 19 | >100 | 10 | >100 | 7 | >100 | 1 | - | 1 | - |
| Votrient | - | - | - | - | - | - | - | - | - | - |
| Vaccines | 436 | 10 | 109 | 34 | 200 | 5 | 61 | (3) | 66 | 7 |
| Boostrix | 13 | (8) | 5 | (29) | 5 | - | - | - | 3 | 50 |
| Cervarix | 12 | - | - | - | 10 | - | 1 | - | 1 | - |
| Fluarix, FluLaval | - | - | - | - | - | - | - | - | - | - |
| Flu Pandemic | 5 | - | - | - | 4 | - | - | - | 1 | - |
| Hepatitis | 139 | 16 | 53 | 66 | 56 | (4) | 12 | (8) | 18 | - |
| Infanrix, Pediarix | 153 | 6 | 51 | 21 | 81 | (1) | 7 | - | 14 | - |
| Rotarix | 27 | 79 | - | - | 9 | 100 | 15 | 56 | 3 | >100 |
| Synflorix | - | - | - | - | - | - | - | - | - | - |
| Dermatologicals | 94 | 1 | 16 | 23 | 29 | (4) | 30 | 4 | 19 | (10) |
| Bactroban | 25 | 14 | 13 | 18 | 6 | - | 5 | - | 1 | 100 |

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

| | | | | | | | | | | |
|-----------------------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|
| Dermovate | - | - | - | - | - | - | - | - | - | - |
| Duac | - | - | - | - | - | - | - | - | - | - |
| Soriatane | - | - | - | - | - | - | - | - | - | - |
| Zovirax | 25 | (15) | 1 | (50) | 8 | (13) | 5 | - | 11 | (18) |
| Other | 220 | 14 | 4 | (91) | 56 | 27 | 57 | - | 103 | 73 |
| | ----- | ----- | ----- | ----- | ----- | ----- | ----- | ----- | ----- | ----- |
| | 4,409 | (4) | 1,986 | (11) | 1,339 | (1) | 448 | 6 | 636 | 6 |
| | ----- | ----- | ----- | ----- | ----- | ----- | ----- | ----- | ----- | ----- |
| ViiV Healthcare (HIV) | 358 | (5) | 152 | (6) | 157 | (7) | 21 | - | 28 | 9 |
| Combivir | 105 | (13) | 45 | (8) | 42 | (21) | 10 | 11 | 8 | (25) |
| Epivir | 34 | (22) | 11 | (21) | 15 | (22) | 3 | (40) | 5 | - |
| Epzicom/Kivexa | 99 | 25 | 40 | 17 | 48 | 33 | 1 | >100 | 10 | 14 |
| Lexiva | 35 | (3) | 18 | (10) | 15 | 8 | 1 | - | 1 | (50) |
| Selzentry | - | - | - | - | - | - | - | - | - | - |
| Trizivir | 54 | (16) | 27 | (16) | 24 | (19) | 1 | - | 2 | - |
| | ----- | ----- | ----- | ----- | ----- | ----- | ----- | ----- | ----- | ----- |
| | 4,767 | (4) | | | | | | | | |
| | ----- | ----- | | | | | | | | |

[End]

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc
(Registrant)

Date: September 10 2010

By: VICTORIA WHYTE

Victoria Whyte
Authorised Signatory for and on
behalf of GlaxoSmithKline plc